EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination

Rui Cheng, Yuanjun Tang, Xuedi Cao, Xiaotong Yu, Zhanya Huang, Yunyun Guo, Renjing Jin, Yan Wang, Yang Liu, Lixiang Xue, Yuqing Wang

British Journal of Pharmacology · 2026-06 · 183 (11) · 2675-2694

DOI: 10.1111/bph.70357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 07.02.2026. Verfasst von Rui Cheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Third Hospital, Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Melanoma, Fenofibrate, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Peking University Third Hospital Clinical Key Project, National Key Research and Development Program of China, Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose EZH2 (enhancer of zeste homologue 2) inhibitors are an emerging class of drugs that target epigenetic regulation. However, their efficacy in solid tumours has been limited, partly due to drug‐induced upregulation of fatty acid synthesis. Combining lipid metabolic modulation with EZH2 inhibition may offer a promising strategy to enhance antitumor activity. Experimental Approach We conducted a screen of clinically approved lipid‐lowering drugs to identify candidates that could enhance the efficacy of EZH2 inhibitors and found that fenofibrate significantly potentiated the antitumor effects of EZH2 inhibition. Mechanistic studies revealed that this synergistic effect was associated with the degradation of EZH2 protein. To uncover the underlying regulatory pathway, we performed mass spectrometry analysis, which identified the E3 ubiquitin ligase TRIM21 and the deubiquitinase OTUD4 as key mediators of fenofibrate‐induced EZH2 degradation. Key Results Fenofibrate significantly enhanced the antitumor effects of EZH2 inhibitors in melanoma, independent of its conventional lipid‐lowering function. TRIM21 and OTUD4 were identified as critical mediators of this synergistic effect. Fenofibrate disrupted the non‐canonical functions of EZH2 by promoting its destabilization, thereby exerting dual effects—inhibiting EZH2 enzymatic activity and accelerating its degradation. Combination therapy with fenofibrate and EZH2 inhibitors resulted in a potent synergistic suppression of tumour growth. Conclusions and Implications Our findings reveal a previously unrecognized role for fenofibrate in augmenting EZH2‐targeted therapy. This study provides a novel strategy to improve the efficacy of epigenetic therapies in cancer by combining EZH2 inhibitors with fenofibrate, offering potential clinical benefits for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinMelanomaFenofibrateAntineoplastic AgentsEndopeptidasesUbiquitin-Specific ProteasesHumansAnimalsTRIM21 ProteinUbiquitinationDrug SynergismCell Line, TumorMiceMice, NudeHypolipidemic Agents

Stichwörter der Autor:innen

EZH2OTUD4TRIM21fenofibratemelanomatargeted therapyubiquitination

Substanzen

Enhancer of Zeste Homolog 2 ProteinTRIM21 ProteinEZH2 protein, humanFenofibrateAntineoplastic AgentsEndopeptidasesHypolipidemic AgentsUbiquitin-Specific Proteases

Autor:innen und Institutionen

  • Peking University Third Hospital, Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
  • Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
  • Cancer Center of Peking University Third Hospital, Beijing, China.
  • Beijing Key Laboratory for Interdisciplinary Research in Gastrointestinal Oncology, Beijing, China.
  • Biobank, Peking University Third Hospital, Beijing, China.

Förderung

  • Peking University Third Hospital Clinical Key Project
  • National Key Research and Development Program of China
  • Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation
  • Fundamental Research Funds for the Central Universities, the General Program of National Natural Science Foundation of China
  • The National Natural Science Foundation of China Youth Fund
  • National Basic Research Program of China

Zitieren

APA

Cheng, R., Tang, Y., Cao, X., Yu, X., Huang, Z., Guo, Y., Jin, R., Wang, Y., Liu, Y., Xue, L., & Wang, Y. (2026). Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination. British Journal of Pharmacology, 183(11), 2675-2694. https://doi.org/10.1111/bph.70357

Vancouver

Cheng R, Tang Y, Cao X, Yu X, Huang Z, Guo Y, et al. Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination. British Journal of Pharmacology. 2026;183(11):2675-2694. doi:10.1111/bph.70357

BibTeX
@article{Cheng2026,
  author = {Cheng, Rui and Tang, Yuanjun and Cao, Xuedi and Yu, Xiaotong and Huang, Zhanya and Guo, Yunyun and Jin, Renjing and Wang, Yan and Liu, Yang and Xue, Lixiang and Wang, Yuqing},
  title = {Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {11},
  pages = {2675--2694},
  doi = {10.1111/bph.70357}
}
Kostenlos starten →